Pathological classification of prostate cancer

Written by Zhou Zi Hua
Oncology
Updated on September 19, 2024
00:00
00:00

The classification of precancerous lesions of prostate cancer is divided into two categories: intraductal carcinoma of the prostate and atypical adenomatous hyperplasia. Among these, the relationship between intraductal carcinoma of the prostate and prostate cancer is the closest. Intraductal carcinoma of the prostate is currently recognized as a precancerous lesion of prostate cancer, while atypical adenomatous hyperplasia has not been proven to be a precancerous lesion of prostate cancer according to current evidence. However, the biological behavior of this atypical adenomatous hyperplasia is not very clear yet, so it should be closely monitored. The histological classification of prostate cancer mainly includes the majority of acinar adenocarcinoma and a small amount of ductal adenocarcinoma, with acinar adenocarcinoma being a highly invasive malignant tumor.

Other Voices

doctor image
home-news-image
Written by Liu Liang
Oncology
45sec home-news-image

Can prostate cancer be detected by ultrasound B?

Prostate cancer can generally be detected through ultrasound, as it reveals nodules in the prostate. By examining the internal echoes of these nodules, one can differentiate between benign and malignant prostate conditions. Thus, in foreign countries, ultrasound, specifically prostate color Doppler ultrasound examinations, are used as a screening method for prostate cancer. In China, screening methods also include traditional digital rectal examinations and generally involve blood tests for specific prostate tumor markers, namely PSA. These tests are combined with prostate ultrasound for a comprehensive assessment.

doctor image
home-news-image
Written by Liu Liang
Oncology
50sec home-news-image

Is chemotherapy for prostate cancer painful?

For patients with advanced prostate cancer, endocrine therapy is primarily used. Chemotherapy is generally chosen when endocrine therapy is resistant and ineffective. The side effects of chemotherapy are similar to those of other chemotherapy treatments. The first is the gastrointestinal side effects, such as nausea, vomiting, decreased appetite, or bloating and abdominal pain. The second is bone marrow suppression, which leads to a decrease in white blood cells and platelets. The side effects of chemotherapy vary with each patient's constitution and other factors. In most cases, with the support of medications for stomach protection, anti-nausea, and increasing white blood cells, the majority of patients can generally tolerate the treatment.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
1min 7sec home-news-image

What are the symptoms of prostate cancer?

Early-stage prostate cancer generally has no symptoms, but if the patient also has prostate enlargement, or in cases of mid to late-stage prostate cancer where the tumor invades the urethra or bladder, various degrees of urinary obstruction or irritative urinary symptoms may occur. This is characterized by frequent urination and urgency. If there are local infiltrative symptoms, perineal pain and sciatica might occur. If the vas deferens is compressed, it can cause back pain and pain in the testicles on the affected side. Invasion of the rectum can cause difficulty in defecation or obstruction of the colon, and if the membranous part of the urethra is involved, urinary incontinence may occur. The most common site of metastasis for prostate cancer is the bones. If it spreads to the bones, it can cause bone pain, pathological fractures, anemia, and spinal cord compression leading to paralysis of the lower limbs.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
51sec home-news-image

Endocrine therapy after radical prostatectomy for prostate cancer

Endocrine therapy after radical prostatectomy for prostate cancer is equivalent to adjuvant endocrine therapy for prostate cancer. Its purpose is to treat residual lesions, positive residual lymph nodes, and microscopic metastatic foci, thereby improving long-term survival rates. Currently, the indications for adjuvant endocrine therapy are based on postoperative pathology-positive results, positive lymph nodes post-surgery, and postoperative pathology confirmation of stage T3 or T4, but with high-risk factors. According to major guidelines, the duration of adjuvant endocrine therapy should be at least eighteen months.

doctor image
home-news-image
Written by Liu Liang
Oncology
51sec home-news-image

Can prostate cancer be cured?

Early-stage prostate cancer patients can achieve a cure through radical surgery or radical radiotherapy and other treatment methods. Therefore, whether prostate cancer can be cured is related to the stage of the patient's condition. Early-stage prostate cancer patients can be cured through radical surgery or radical radiotherapy. If the cancer is diagnosed at a late stage, with extensive pelvic metastasis or multiple bone metastases, treatment for these late-stage prostate cancer patients primarily revolves around endocrine therapy. Most patients respond well to endocrine treatment; however, for these late-stage prostate cancer patients, the treatment aims to alleviate symptoms and extend survival. Through these treatments, a cure is not achievable.